The dF508 mutation represents the most common cause underlying cystic fibrosis. The resultant misfolding of the nascent cystic fibrosis transmembrane regulator (CFTR) protein and its subsequent proteasomal degradation lead to a deficiency in functional CFTR channels and Cl- efflux at the apical cell membrane in ducts throughout the body (Veit et al. 2016).
Here we share a short video introducing Metrion’s expanded high throughput screening capabilities. To learn more, or to request a quote, please email info@metrionbiosciences.com
The development of Automated Patch Clamp (APC) technology over the last 20 years has
transformed the research and development process for identifying novel drugs for ion channel targets.
Here we share a short video introducing Metrion’s extensive suite of cardiac safety screening services. To learn more, or to request a quote, please email info@metrionbiosciences.com
Watch on demand the Metrion Biosciences webinar presented by Manoj K. Patel, Ph.D, Associate Professor at the University of Virginia where he speaks about “Gain-of-function mutations in Nav1.6 and epileptic seizures“.
The webinar took place on Thursday 29th November 2022 at 16:00 EDT.
Ridley, J., Manyweathers, S., Tang, R., Goetze, T., Becker, N., Kirby, R., Obergrussberger, A., & Rogers, M. (2022). Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms. Frontiers in Molecular Neuroscience. Frontiers in Molecular Neuroscience, 2022.https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.982689/full
Metrion Biosciences is a specialist ion channel contract research organisation providing drug discovery services to pharmaceutical and bioscience customers worldwide. Discover more about our capabilities and facilities in this short introductory video.
Dr. Kris Kahlig is the Head of Biology at Praxis Precision Medicines Inc. a clinical stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by CNS disorders. Kris presented at the Metrion Webinar series on “Using Dynamic Action Potential Clamp Modelling of Nav1.2 Variants to Support the Prediction of Clinical Phenotype in DEE”.
The webinar took place on Thursday 5th May 2022 at 16:00 BST.
We are delighted to present the fourth speaker in our “Ion Channels in Drug Discovery” webinar series – Dr. Greg Carr from the Lieber Institute for Brain Development. Greg’s presentation was entitled: “A role for hERG potassium channels in cognitive function”
The webinar took place on Thursday 3rd February 2022 at 16:00 BST.
We are delighted to present the third speaker in our webinar series – Professor David Sheppard from the University of Bristol. David’s presentation was focused on Cystic Fibrosis and his talk was “Cystic Fibrosis: Rescuing Faulty Channels with Targeted Therapies”.
The webinar took place on Tuesday 30th November 2021 at 16:00 BST.